Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),,38,2301,DB01267,Paliperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],67,2302,DB01267,Paliperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],99,2303,DB01267,Paliperidone
,15665755,serum concentrations,"The median serum concentrations of risperidone plus 9-hydroxyrisperidone were 38 nmol/L 12-14 days after a intramuscular dose of 25 mg/14 days, 67 nmol/L after a dose of 37.5 mg/14 days, 99 nmol/L after a dose of 50 mg/14 days, and 148 nmol/L after a dose of 75 mg/14 days.",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[nM] / [l],148,2304,DB01267,Paliperidone
,15665755,C/D ratio,The median C/D ratio for risperidone plus 9-hydroxy-risperidone was 22.2 (nmol/L)/(mg/d).,Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[l·nmol] / [d·mg],22.2,2305,DB01267,Paliperidone
,15665755,C/D ratio,"In the group on oral medication, the median C/D ratio was 18.6 (nmol/L)/(mg/d).",Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665755/),[l·nM] / [d·mg],18.6,2306,DB01267,Paliperidone
,31774943,Dose-corrected AM levels,Dose-corrected AM levels were more than doubled in the 30-60 mL/min/1.73 m² group compared to the > 90-120 mL/min/1.73 m² group (mean ± SD = 22.2 ± 14.0 [ng/mL]/[mg/d] vs 10.1 ± 7.7 [ng/mL]/[mg/d]).,Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774943/),[ng] / [ml],22.2,7110,DB01267,Paliperidone
,31774943,Dose-corrected AM levels,Dose-corrected AM levels were more than doubled in the 30-60 mL/min/1.73 m² group compared to the > 90-120 mL/min/1.73 m² group (mean ± SD = 22.2 ± 14.0 [ng/mL]/[mg/d] vs 10.1 ± 7.7 [ng/mL]/[mg/d]).,Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774943/),[ng] / [ml],10.1,7111,DB01267,Paliperidone
,26412032,oral bioavailability,The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER.,Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26412032/),%,51,14808,DB01267,Paliperidone
,26412032,oral bioavailability,The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER.,Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26412032/),%,52,14809,DB01267,Paliperidone
,30628010,Tmax,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),h,2,17004,DB01267,Paliperidone
,30628010,Cmax,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),[ng] / [ml],8,17005,DB01267,Paliperidone
,30628010,half-life,"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),h,3.5,17006,DB01267,Paliperidone
,30628010,area under the plasma concentration-time curve from time zero to infinity (AUC0-∞),"VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), 58.2 ng h2/mL.","Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30628010/),[h2·ng] / [ml],58.2,17007,DB01267,Paliperidone
,17825699,C(max),"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],15.9,20859,DB01267,Paliperidone
,17825699,t(1/2),"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),h,3.0,20860,DB01267,Paliperidone
,17825699,AUC 0 to 12 hours,"Mean (SD) values for C(max), t(1/2), and AUC 0 to 12 hours for risperidone in plasma were 15.9 (22.2) ng/mL, 3.0 (2.3) h, and 92.1 (200.6) ng x h/mL, respectively.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],92.1,20861,DB01267,Paliperidone
,17825699,C(max),"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],13.6,20862,DB01267,Paliperidone
,17825699,C(max),"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[ng] / [ml],4.9,20863,DB01267,Paliperidone
,17825699,AUC,"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],73.6,20864,DB01267,Paliperidone
,17825699,AUC,"Mean (SD) plasma enantiomer values for C(max) and AUC calculated up to the last observation were: (+)-9-OH-risperidone, 13.6 (10.0) ng/mL and 73.6 (52.3) ng x h/mL; (-)-9-OH-risperidone, 4.9 (3.1) ng/mL and 29.3 (19.1) ng x h/mL.",Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825699/),[h·ng] / [ml],29.3,20865,DB01267,Paliperidone
,11823895,terminal elimination half-life (t(1/2) ),The terminal elimination half-life (t(1/2) ) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h).,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,17.6,24560,DB01267,Paliperidone
,11823895,terminal elimination half-life (t(1/2) ),The terminal elimination half-life (t(1/2) ) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h).,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,1.2,24561,DB01267,Paliperidone
,11823895,t(1/2),The t(1/2)of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (approximately 8-11 h) than that for RSP but it was longer in the spleen.,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,3.4,24562,DB01267,Paliperidone
,11823895,t(1/2),The t(1/2)of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (approximately 8-11 h) than that for RSP but it was longer in the spleen.,"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823895/),h,8-11,24563,DB01267,Paliperidone
,17702401,Rate constant,"Rate constant of RIP conversion to 9-hydroxyrisperidone was (0.12 +/- 0.08) h(-1) and (0.014 +/- 0.007) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.12,33431,DB01267,Paliperidone
,17702401,Rate constant,"Rate constant of RIP conversion to 9-hydroxyrisperidone was (0.12 +/- 0.08) h(-1) and (0.014 +/- 0.007) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.014,33432,DB01267,Paliperidone
,17702401,Elimination rate constants,"Elimination rate constants of RIP were (0.25 +/- 0.18) and (0.05 +/- 0.23) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.25,33433,DB01267,Paliperidone
,17702401,Elimination rate constants,"Elimination rate constants of RIP were (0.25 +/- 0.18) and (0.05 +/- 0.23) h(-1) for EM and IM, respectively.",[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702401/),1/[h],0.05,33434,DB01267,Paliperidone
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,26.9,47531,DB01267,Paliperidone
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,17.1,47532,DB01267,Paliperidone
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,15.9,47533,DB01267,Paliperidone
,22888277,half-life,"Due to the long half-life of paliperidone palmitate (25-49 days), putative therapeutic plasma concentrations persisted longest in simulated cases of complete discontinuation or treatment interruption.",Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888277/),d,25-49,51826,DB01267,Paliperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],9.38,52217,DB01267,Paliperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],29.2,52218,DB01267,Paliperidone
,22929407,Clearance,"Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h.",Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929407/),[l] / [h],37.4,52219,DB01267,Paliperidone
,19713555,terminal half-life,Paliperidone is eliminated with a terminal half-life of approximately 24 hours.,Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19713555/),h,24,67441,DB01267,Paliperidone
,29404931,AUClast,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],216.1,68262,DB01267,Paliperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],220.5,68263,DB01267,Paliperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],221.6,68264,DB01267,Paliperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],226.4,68265,DB01267,Paliperidone
,29404931,AUC∞,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.7,68266,DB01267,Paliperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[h·ng] / [ml],226.4,68267,DB01267,Paliperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.7,68268,DB01267,Paliperidone
,29404931,Cmax,"The pharmacokinetic parameters of AUClast, AUC∞ and Cmax for the 18 subjects after a single oral dose of the trial or reference preparation were 216.1 ± 88.7 and 220.5 ± 96.8 ng·h/mL; 221.6 ± 93.1 and 226.4 ± 103.5 ng·h/mL; 36.7 ± 10.3 and 36.0 ± 10.2 ng/mL, respectively.",Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404931/),[ng] / [ml],36.0,68269,DB01267,Paliperidone
,22632481,Terminal half-life,Terminal half-life is approximately 23 h.,"Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632481/),h,23,79658,DB01267,Paliperidone
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,19,83624,DB01267,Paliperidone
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,3,83625,DB01267,Paliperidone
,7520903,half-life,"However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the ""active fraction"" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers.",The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,20,83626,DB01267,Paliperidone
,24676998,time to reach Cmax (tmax ),Median time to reach Cmax (tmax ) ranged from 13-14 days after deltoid and 13-17 days after gluteal injection across all doses.,"A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676998/),d,13-14,93773,DB01267,Paliperidone
,24676998,time to reach Cmax (tmax ),Median time to reach Cmax (tmax ) ranged from 13-14 days after deltoid and 13-17 days after gluteal injection across all doses.,"A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676998/),d,13-17,93774,DB01267,Paliperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,411.28,95648,DB01267,Paliperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,191.15,95649,DB01267,Paliperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,427.30,95650,DB01267,Paliperidone
,16775814,m/z,The mass transition ion-pair was followed as m/z 411.28 --> 191.15 for RSP and m/z 427.30 --> 207.10 for 9-OH-RSP.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),,207.10,95651,DB01267,Paliperidone
,16775814,overall recoveries,"The overall recoveries for RSP and 9-OH-RSP were 82.1% and 83.2%, respectively.",Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),%,82.1,95652,DB01267,Paliperidone
,16775814,overall recoveries,"The overall recoveries for RSP and 9-OH-RSP were 82.1% and 83.2%, respectively.",Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),%,83.2,95653,DB01267,Paliperidone
,16775814,total analysis time,The total analysis time was as low as 3.0 min only.,Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775814/),min,3.0,95654,DB01267,Paliperidone
,10862124,analysis time,The analysis time for each sample was 4 min and more than 100 samples could be analyzed in one day by running the system overnight.,Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10862124/),min,4,97773,DB01267,Paliperidone
,17460786,time-to-peak plasma concentration,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24.1,98845,DB01267,Paliperidone
,17460786,elimination half-life,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24,98846,DB01267,Paliperidone
,7531352,apparent elimination half-life,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.0,108472,DB01267,Paliperidone
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.5,108473,DB01267,Paliperidone
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,2.5,108474,DB01267,Paliperidone
,7531352,half-lives,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,3-4,108475,DB01267,Paliperidone
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,4-6,108476,DB01267,Paliperidone
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,12,108477,DB01267,Paliperidone
,11076069,flow-rate,"The mobile phase consisted of phosphate buffer (0.05 M, pH 3.7 with 25% H3PO4)-acetonitrile (70:30, v/v), and was delivered at a flow-rate of 1.0 ml/min.",Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),[ml] / [min],1.0,111533,DB01267,Paliperidone
,11076069,total time,The peaks were detected using a UV detector set at 278 nm and the total time for a chromatographic separation was about 4 min.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),min,4,111534,DB01267,Paliperidone
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,98.0,111535,DB01267,Paliperidone
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,83.5,111536,DB01267,Paliperidone
,24845884,"Dv,50","A paliperidone palmitate (PPP) long-acting suspension was characterized with regard to particle size (Dv,50 = 1.09 μm) and morphology prior to i.m. injection in rats.",Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845884/),μm,1.09,114664,DB01267,Paliperidone
,24845884,time of occurrence of observed maximum drug plasma concentration,This was associated with a decrease in apparent paliperidone (PP) absorption (near-zero order) until 96 h and a delayed time of occurrence of observed maximum drug plasma concentration (168 h).,Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845884/),h,168,114665,DB01267,Paliperidone
,34286598,percentage entrapment efficiency,"Results: NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV.",Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286598/),%,83.44,116851,DB01267,Paliperidone
,34286598,polydispersity index,"Results: NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV.",Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286598/),,0.143,116852,DB01267,Paliperidone
,20683501,half-life,"After intramuscular injection, paliperidone palmitate is slowly hydrolyzed to paliperidone with a mean half-life of 24-49 days, depending on the dose.","Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683501/),d,24-49,128805,DB01267,Paliperidone
,29642738,area under the curve (AUC; 0-28) days,"The exposures (i.e. area under the curve (AUC; 0-28) days) were 18,597, 21,865 and 18,120 ng.h/mL, in Wistar, SD and rabbits, respectively.",Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29642738/),[h·ng] / [ml],"18,597",130312,DB01267,Paliperidone
,29642738,area under the curve (AUC; 0-28) days,"The exposures (i.e. area under the curve (AUC; 0-28) days) were 18,597, 21,865 and 18,120 ng.h/mL, in Wistar, SD and rabbits, respectively.",Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29642738/),[h·ng] / [ml],"21,865",130313,DB01267,Paliperidone
,29642738,area under the curve (AUC; 0-28) days,"The exposures (i.e. area under the curve (AUC; 0-28) days) were 18,597, 21,865 and 18,120 ng.h/mL, in Wistar, SD and rabbits, respectively.",Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29642738/),[h·ng] / [ml],"18,120",130314,DB01267,Paliperidone
,29642738,half-life,The clearance was slow and supported long half-life (8-10 days).,Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29642738/),d,8-10,130315,DB01267,Paliperidone
,27743205,Apparent clearance (CL),"Apparent clearance (CL), apparent volume of distribution (V), and fraction of the absorbed dose (F3) were estimated to be 3.84 l/h, 1960 L, and 20.9 %.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),[l] / [h],3.84,130319,DB01267,Paliperidone
,27743205,apparent volume of distribution (V),"Apparent clearance (CL), apparent volume of distribution (V), and fraction of the absorbed dose (F3) were estimated to be 3.84 l/h, 1960 L, and 20.9 %.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),l,1960,130320,DB01267,Paliperidone
,27743205,fraction of the absorbed dose (F3),"Apparent clearance (CL), apparent volume of distribution (V), and fraction of the absorbed dose (F3) were estimated to be 3.84 l/h, 1960 L, and 20.9 %.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),%,20.9,130321,DB01267,Paliperidone
,27743205,maximum absorption rate constant (k a1 max),"For slow absorption, the maximum absorption rate constant (k a1 max), amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt1 50), and Hill factor (γ) were estimated to be 90.4 µg/h, 120 mg, and 1.44, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),[μg] / [h],90.4,130322,DB01267,Paliperidone
,27743205,k amt1 50,"For slow absorption, the maximum absorption rate constant (k a1 max), amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt1 50), and Hill factor (γ) were estimated to be 90.4 µg/h, 120 mg, and 1.44, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),mg,120,130323,DB01267,Paliperidone
,27743205,Hill factor (γ),"For slow absorption, the maximum absorption rate constant (k a1 max), amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt1 50), and Hill factor (γ) were estimated to be 90.4 µg/h, 120 mg, and 1.44, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),,1.44,130324,DB01267,Paliperidone
,27743205,maximum absorption rate constant (k a3 max),"For rapid absorption, the maximum absorption rate constant (k a3 max) and amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt3 50) were estimated to be 164 µg/h and 21.4 mg, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),[μg] / [h],164,130325,DB01267,Paliperidone
,27743205,half of the maximum absorption rate was achieved (,"For rapid absorption, the maximum absorption rate constant (k a3 max) and amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt3 50) were estimated to be 164 µg/h and 21.4 mg, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),[μg] / [h],164,130326,DB01267,Paliperidone
,27743205,k amt3 50),"For rapid absorption, the maximum absorption rate constant (k a3 max) and amount of paliperidone at the absorption site when half of the maximum absorption rate was achieved (k amt3 50) were estimated to be 164 µg/h and 21.4 mg, respectively.",Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27743205/),mg,21.4,130327,DB01267,Paliperidone
,16460829,oral bioavailability,The oral bioavailability of the polymer was 40%.,Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16460829/),%,40,131555,DB01267,Paliperidone
,26189570,apparent half-life,"Peak paliperidone plasma concentration was achieved between 23 and 34 days, and apparent half-life was ∼2-4 months.","Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189570/),month,∼2-4,132179,DB01267,Paliperidone
,26189570,Relative bioavailability,Relative bioavailability in comparison with paliperidone was ∼100% independent of the dose and injection site.,"Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189570/),%,∼100,132180,DB01267,Paliperidone
,19457210,serum concentration,"The mean serum concentration of risperidone plus 9-hydroxyrisperidone was 29.1 ng/mL at the 12th week after switching, with an average injection dose of 31.25 mg long-acting risperidone every two weeks.",Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19457210/),[ng] / [ml],29.1,136521,DB01267,Paliperidone
,19825908,C(max),"Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[ng] / [ml],71.8,139011,DB01267,Paliperidone
,19825908,C(max),"Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[ng] / [ml],89.7,139012,DB01267,Paliperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],1389,139013,DB01267,Paliperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],842,139014,DB01267,Paliperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],1306,139015,DB01267,Paliperidone
,19825908,AUC(0-24 h),"On day 6, serum prolactin concentration-time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC(0-24 h): 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively).",A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825908/),[h·ng] / [ml],741,139016,DB01267,Paliperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.06,139294,DB01267,Paliperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.07,139295,DB01267,Paliperidone
,21194608,relative bioavailabilities,"The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively.","Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194608/),,1.04,139296,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,71.0,140211,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,54.0,140212,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,74.4,140213,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,65.4,140214,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,81.5,140215,DB01267,Paliperidone
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,75.0,140216,DB01267,Paliperidone
,30449206,concentration/dose (C/D) ratio,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141549,DB01267,Paliperidone
,30449206,clearance,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141550,DB01267,Paliperidone
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,96.8,147712,DB01267,Paliperidone
,12450541,recoveries,"The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively.",Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450541/),%,99.4,147713,DB01267,Paliperidone
,26129833,flow rate,The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C.,"Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),[ml] / [min],0.3,153465,DB01267,Paliperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,0.9,153466,DB01267,Paliperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.4,153467,DB01267,Paliperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,.,153468,DB01267,Paliperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.8,153469,DB01267,Paliperidone
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,3.1,153470,DB01267,Paliperidone
,26129833,total run time,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,4,153471,DB01267,Paliperidone
,28821438,area under the concentration-time curve,"The rat group infused with ILE showed a higher area under the concentration-time curve (mean [S.D.]: 6102 [900.9] vs. 3407 [992.1]nghml-1, p=0.02) and longer elimination half-time (t1/2) (4.1 [0.9] vs. 2.2 [0.4]h, p=0.02) compared with the AR group.",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),1/[nghml],6102,154242,DB01267,Paliperidone
,28821438,area under the concentration-time curve,"The rat group infused with ILE showed a higher area under the concentration-time curve (mean [S.D.]: 6102 [900.9] vs. 3407 [992.1]nghml-1, p=0.02) and longer elimination half-time (t1/2) (4.1 [0.9] vs. 2.2 [0.4]h, p=0.02) compared with the AR group.",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),1/[nghml],3407,154243,DB01267,Paliperidone
,28821438,elimination half-time (t1/2),"The rat group infused with ILE showed a higher area under the concentration-time curve (mean [S.D.]: 6102 [900.9] vs. 3407 [992.1]nghml-1, p=0.02) and longer elimination half-time (t1/2) (4.1 [0.9] vs. 2.2 [0.4]h, p=0.02) compared with the AR group.",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),h,4.1,154244,DB01267,Paliperidone
,28821438,elimination half-time (t1/2),"The rat group infused with ILE showed a higher area under the concentration-time curve (mean [S.D.]: 6102 [900.9] vs. 3407 [992.1]nghml-1, p=0.02) and longer elimination half-time (t1/2) (4.1 [0.9] vs. 2.2 [0.4]h, p=0.02) compared with the AR group.",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),h,2.2,154245,DB01267,Paliperidone
,28821438,Tissue/plasma concentration ratios,"Tissue/plasma concentration ratios of paliperidone were lower in ILE rats than in AR rats (1.98 [0.70] vs. 3.82 [1.47] in the heart, p=0.04; 0.28 [0.29] vs. 1.27 [0.58] in the brain, p<0.001).",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),,1.98,154246,DB01267,Paliperidone
,28821438,Tissue/plasma concentration ratios,"Tissue/plasma concentration ratios of paliperidone were lower in ILE rats than in AR rats (1.98 [0.70] vs. 3.82 [1.47] in the heart, p=0.04; 0.28 [0.29] vs. 1.27 [0.58] in the brain, p<0.001).",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),,3.82,154247,DB01267,Paliperidone
,28821438,Tissue/plasma concentration ratios,"Tissue/plasma concentration ratios of paliperidone were lower in ILE rats than in AR rats (1.98 [0.70] vs. 3.82 [1.47] in the heart, p=0.04; 0.28 [0.29] vs. 1.27 [0.58] in the brain, p<0.001).",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),,0,154248,DB01267,Paliperidone
,28821438,Tissue/plasma concentration ratios,"Tissue/plasma concentration ratios of paliperidone were lower in ILE rats than in AR rats (1.98 [0.70] vs. 3.82 [1.47] in the heart, p=0.04; 0.28 [0.29] vs. 1.27 [0.58] in the brain, p<0.001).",Effect of lipid emulsion infusion on paliperidone pharmacokinetics in the acute overdose rat model: A potential emergency treatment for paliperidone intoxication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28821438/),,1.27,154249,DB01267,Paliperidone
,16490177,Tmax,Risperidone was rapidly absorbed (Tmax was 1.6 h) and its T1/2 in plasma was short (3.2 h).,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,1.6,172573,DB01267,Paliperidone
,16490177,T1/2,Risperidone was rapidly absorbed (Tmax was 1.6 h) and its T1/2 in plasma was short (3.2 h).,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,3.2,172574,DB01267,Paliperidone
,16490177,Tmax,9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h.,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,2.5,172575,DB01267,Paliperidone
,16490177,half-life,It had a long half-life of 24.7 h.,Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),h,24.7,172576,DB01267,Paliperidone
,16490177,C(ss)(av),"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],36.9,172577,DB01267,Paliperidone
,16490177,C(ss)(av),"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],110.6,172578,DB01267,Paliperidone
,16490177,AUC(ss)0-12,"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],443.2,172579,DB01267,Paliperidone
,16490177,AUC(ss)0-12,"The C(ss)(av) of risperidone and 9-hydroxy-risperidone were 36.9+/-33.1 and 110.6+/-30.5 microg x h x L(-1), respectively, and the AUC(ss)0-12 were 443.2+/- 397.4 and 1327.2+/- 402.3 microg x h x L(-1), respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[h·μg] / [l],1327.2,172580,DB01267,Paliperidone
,16490177,CL/F,"CL/F and V/F of risperidone were 8.7+/- 6.2 L/h and 34.1+/- 24.3 L, respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),[l] / [h],8.7,172581,DB01267,Paliperidone
,16490177,V/F,"CL/F and V/F of risperidone were 8.7+/- 6.2 L/h and 34.1+/- 24.3 L, respectively.",Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490177/),l,34.1,172582,DB01267,Paliperidone
higher,34142360,C/D,"However, male patients receiving PP1M every 28 days with C/D values higher than 7.7 (ng/mL)/(mg/day) showed a higher risk for ADRs, implying that therapeutic drug monitoring may be useful in assessing the risk of PP1M-related ADRs.",Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34142360/),[ml·ng] / [day·mg],7.7,193756,DB01267,Paliperidone
,22455454,mode dose,Mean (SD) mode dose of PP was 144.8 (19.58) mg eq.,"A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22455454/),e·mg,144.8,195602,DB01267,Paliperidone
,22455454,concentrations,"The dosing initiation regimen resulted in rapidly achieved and maintained therapeutic paliperidone levels over the study (average concentrations during the dosing interval were 34.7, 40.0, and 47.8 ng/mL after the 2nd, 8th, and 14th injection respectively).","A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22455454/),,40,195603,DB01267,Paliperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,25-48,215766,DB01267,Paliperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,59-83,215767,DB01267,Paliperidone
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,62-72,215768,DB01267,Paliperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),,4.4-8.8,215769,DB01267,Paliperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],15.0-31.1,215770,DB01267,Paliperidone
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],22.5-26.3,215771,DB01267,Paliperidone
,12469003,maximum concentration,The maximum concentration of unaltered RIS was 325 ng/mL and that of the principal metabolite (9-hydroxy-risperidone: 9-OH RIS) was 139 ng/mL.,Sequential changes in the plasma concentration of risperidone following intentional overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),[ng] / [ml],325,218561,DB01267,Paliperidone
,12469003,maximum concentration,The maximum concentration of unaltered RIS was 325 ng/mL and that of the principal metabolite (9-hydroxy-risperidone: 9-OH RIS) was 139 ng/mL.,Sequential changes in the plasma concentration of risperidone following intentional overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),[ng] / [ml],139,218562,DB01267,Paliperidone
,12469003,half-life,"By plotting the time-concentration curve for the active fraction (RIS plus 9-OH-RIS) in the first and second patients, the half-life of RIS following overdose was determined and was approximately 12.7 hr and 17.8 hr, respectively.",Sequential changes in the plasma concentration of risperidone following intentional overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),h,12.7,218563,DB01267,Paliperidone
,12469003,half-life,"By plotting the time-concentration curve for the active fraction (RIS plus 9-OH-RIS) in the first and second patients, the half-life of RIS following overdose was determined and was approximately 12.7 hr and 17.8 hr, respectively.",Sequential changes in the plasma concentration of risperidone following intentional overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12469003/),h,17.8,218564,DB01267,Paliperidone
,17344104,LLOQ,LLOQ for all analytes was 0.2 ng/mL.,Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344104/),[ng] / [ml],0.2,232764,DB01267,Paliperidone
,17344104,sample run time,The sample run time was 8 min.,Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344104/),min,8,232765,DB01267,Paliperidone
,21118746,C(max),"For RSP, mean (SD) C(max) values were 12.6 (2.7) and 16.0 (2.3) ng/mL for the test and reference formulations, respectively.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],12.6,234057,DB01267,Paliperidone
,21118746,C(max),"For RSP, mean (SD) C(max) values were 12.6 (2.7) and 16.0 (2.3) ng/mL for the test and reference formulations, respectively.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],16.0,234058,DB01267,Paliperidone
,21118746,Cmax,"For 9-OH-RSP, mean Cmax values were 17.8 (1.3) and 21.0 (1.7) ng/mL for the test and reference formulations.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],17.8,234059,DB01267,Paliperidone
,21118746,Cmax,"For 9-OH-RSP, mean Cmax values were 17.8 (1.3) and 21.0 (1.7) ng/mL for the test and reference formulations.","Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118746/),[ng] / [ml],21.0,234060,DB01267,Paliperidone
,29040230,concentration/dose (C/D) ratio,"The median concentration/dose (C/D) ratio of paliperidone was 16.1 (nmol/L)/(mg/d), with a 10-90 percentile range of 7.8-31.0 (nmol/L)/(mg/d).",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,16.1,237324,DB01267,Paliperidone
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,31,237325,DB01267,Paliperidone
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,53,237326,DB01267,Paliperidone
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),[nM] / [l],59,237327,DB01267,Paliperidone
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),[nM] / [l],93,237328,DB01267,Paliperidone
,32476097,metabolic ratio,"One inpatient was identified as a potential PM, showing a metabolic ratio of 3.39.",Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32476097/),,3.39,239927,DB01267,Paliperidone
,18761856,half-life,Its half-life is about 24 hours.,[Paliperidone--a novel second-generation antipsychotic]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761856/),h,24,262513,DB01267,Paliperidone
,18058087,receptor,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,54.2-85.5,266897,DB01267,Paliperidone
,18058087,occupancies,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,54.2-85.5,266898,DB01267,Paliperidone
,18058087,occupancies,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,34.5-87.3,266899,DB01267,Paliperidone
,18058087,ED50,"ED50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),[mg] / [d],2.38,266900,DB01267,Paliperidone
,18058087,ED50,"ED50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),[mg] / [d],2.84,266901,DB01267,Paliperidone
,20589922,t(max),"Paliperidone was well absorbed (median t(max): 24 h after a 3-mg dose, and 26 h after a 9-mg dose).",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,24,267832,DB01267,Paliperidone
,20589922,t(max),"Paliperidone was well absorbed (median t(max): 24 h after a 3-mg dose, and 26 h after a 9-mg dose).",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,26,267833,DB01267,Paliperidone
,20589922,t(1/2),"Pharmacokinetics was linear with respect to time; Geometric mean t(1/2) was 22.8 h and 21.4 h in 3-mg and 9-mg groups, respectively.",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,22.8,267834,DB01267,Paliperidone
,20589922,t(1/2),"Pharmacokinetics was linear with respect to time; Geometric mean t(1/2) was 22.8 h and 21.4 h in 3-mg and 9-mg groups, respectively.",Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20589922/),h,21.4,267835,DB01267,Paliperidone
,30498351,TTO,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,17,269553,DB01267,Paliperidone
,30498351,TTO,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,115,269554,DB01267,Paliperidone
,30498351,TTO,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,98.5,269555,DB01267,Paliperidone
,30498351,TTR,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,36.5,269556,DB01267,Paliperidone
,30498351,TTR,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,91,269557,DB01267,Paliperidone
,30498351,TTR,"Among patients with reported EPS-related TEAEs, the median TTO for all EPS-related TEAEs was 17 days (PP1M) in OL phase and 115 days (PP3M) and 98.5 days (PP1M) in DB phase; median TTR was 36.5 days (PP1M) in OL phase and 91 days (PP3M) and 85.5 days (PP1M) in DB phase.",Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498351/),d,85.5,269558,DB01267,Paliperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],12.9,273082,DB01267,Paliperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],36,273083,DB01267,Paliperidone
,18771484,CL,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),[l] / [h],65.4,273084,DB01267,Paliperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,25,273085,DB01267,Paliperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,8.5,273086,DB01267,Paliperidone
,18771484,half-life,"Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.",Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771484/),h,4.7,273087,DB01267,Paliperidone
